Download PDF
Seminars in Neurosurgery 2003; 14(3): 169-186
DOI: 10.1055/s-2004-817734
Copyright © 2002 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Pathophysiology of Meningiomas

Brian Ragel1 , Randy L. Jensen1,2,3
  • 1Department of Neurosurgery, University of Utah, Salt Lake City, Utah
  • 2Neurosurgical Section, Surgical Service, Department of Veterans Affairs (VA), Salt Lake City Health Care System, Salt Lake City, Utah
  • 3Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah
Further Information

Publication History

Publication Date:
02 June 2004 (online)

    Permissions and Reprints

ABSTRACT

This article provides a brief description of the current knowledge of meningioma tumorigenesis and biology. Meningioma grade, subtyping, histology, and MIB-1 labeling index are discussed in relationship to tumor behavior and recurrence prediction. Chromosomal abnormalities associated with meningioma development are discussed with an emphasis on chromosome 22 and the neurofibromatosis type 2 gene. The current knowledge of prognostic features of 1p deletions is outlined. The role of sex hormones in meningioma growth and development is also discussed and summarized. To date, treatment regimens based on inhibiting hormonally mediated meningioma growth have been disappointing. Research concerning growth factors and peptide hormones that have been implicated in meningioma tumorigenesis is discussed. It is hoped that further understanding of the biology of meningioma development, growth, and angiogenesis will lead to new successful treatments for refractory meningiomas.

KEYWORDS

Meningioma tumorigenesis - tumor grading - histology - prognosis

REFERENCES

  • 1 Al-Rodhan R F, Laws E R. The history of intracranial meningiomas. In: Al-Mefty O, ed. Meningiomas New York: Raven Press 1991: 1-6
    Google Scholar
  • 2 Carroll R S, Zhang J, Black P M. Expression of estrogen receptors alpha and beta in human meningiomas.  J Neurooncol . 1999;  42 109-116
    CrossrefPubMedGoogle Scholar
  • 3 Catala M. Embryonic and fetal development of structures associated with the cerebro-spinal fluid in man and other species. Part I: The ventricular system, meninges and choroid plexuses.  Arch Anat Cytol Pathol . 1998;  46 153-169
    PubMedGoogle Scholar
  • 4 Burger P C, Scheithauer B W, Vogel F S. Surgical Pathology of the Nervous System and Its Coverings 4th ed.  Philadelphia: Churchill Livingstone; 2002: 49-71
    Google Scholar
  • 5 Osborn A G. Diagnostic Neuroradiology.  St. Louis: Mosby 1994: 584-601
    Google Scholar
  • 6 Mahmood A, Caccamo D V, Tomecek F J, Malik G M. Atypical and malignant meningiomas: a clinicopathological review.  Neurosurgery . 1993;  33 955-963
    PubMedGoogle Scholar
  • 7 Gonzales M F. Classification of brain tumors. In: Kaye AH, Laws ER, eds. Brain Tumors 1st ed: Edinburgh: Churchill Livingstone 1995: 675
    Google Scholar
  • 8 Louis D N, Scheithauer B W, Budka H, von Deimling A, Kepes J J. Meningiomas. In: Kleihues P, Cavenee WK, eds. World Health Organization Classification of Tumours: Pathology and Genetics: Tumours of the Nervous System Lyon: IARC Press; 2000: 175-189
    Google Scholar
  • 9 Jaaskelainen J, Haltia M, Servo A. Atypical and anaplastic meningiomas: radiology, surgery, radiotherapy, and outcome.  Surg Neurol . 1986;  25 233-242
    PubMedGoogle Scholar
  • 10 Nakasu S, Li D H, Okabe H, Nakajima M, Matsuda M. Significance of MIB-1 staining indices in meningiomas: comparison of two counting methods.  Am J Surg Pathol . 2001;  25 472-478
    CrossrefPubMedGoogle Scholar
  • 11 Ho D M, Hsu C Y, Ting L T, Chiang H. Histopathology and MIB-1 labeling index predicted recurrence of meningiomas: a proposal of diagnostic criteria for patients with atypical meningioma.  Cancer . 2002;  94 1538-1547
    CrossrefPubMedGoogle Scholar
  • 12 Lanzafame S, Torrisi A, Barbagallo G, Emmanuele C, Alberio N, Albanese V. Correlation between histological grade, MIB-1, p53, and recurrence in 69 completely resected primary intracranial meningiomas with a 6 year mean follow-up.  Pathol Res Pract . 2000;  196 483-488
    PubMedGoogle Scholar
  • 13 Korshunov A, Shishkina L, Golanov A. DNA topoisomerase II-alpha and cyclin A immunoexpression in meningiomas and its prognostic significance.  Arch Pathol Lab Med . 2002;  126 1079-1086
    PubMedGoogle Scholar
  • 14 Kamei Y, Watanabe M, Nakayama T, Kanamaru K, Waga S, Shiraishi T. Prognostic significance of p53 and p21WAF1/ CIP1 immunoreactivity and tumor micronecrosis for recurrence of meningiomas.  J Neurooncol . 2000;  46 205-213
    CrossrefPubMedGoogle Scholar
  • 15 Abramovich C M, Prayson R A. Apoptotic activity and bcl-2 immunoreactivity in meningiomas. Association with grade and outcome.  Am J Clin Pathol . 2000;  114 84-92
    CrossrefPubMedGoogle Scholar
  • 16 Bostrom J, Meyer-Puttlitz B, Wolter M. et al . Alterations of the tumor suppressor genes CDKN2A (p16(INK4a)), p14(ARF), CDKN2B (p15(INK4b)), and CDKN2C (p18(INK4c)) in atypical and anaplastic meningiomas.  Am J Pathol . 2001;  159 661-669
    PubMedGoogle Scholar
  • 17 Comtesse N, Heckel D, Racz A, Brass N, Glass B, Meese E. Five novel immunogenic antigens in meningioma: cloning, expression analysis, and chromosomal mapping.  Clin Cancer Res . 1999;  5 3560-3568
    PubMedGoogle Scholar
  • 18 Weisberg S, Ashkenazi E, Israel Z. et al . Anaplastic and atypical meningiomas express high levels of Fas and undergo apoptosis in response to Fas ligation.  Am J Pathol . 2001;  159 1193-1197
    PubMedGoogle Scholar
  • 19 Kilic T, Bayri Y, Ozduman K. et al . Tenascin in meningioma: expression is correlated with anaplasia, vascular endothelial growth factor expression, and peritumoral edema but not with tumor border shape.  Neurosurgery . 2002;  51 183-193
    CrossrefPubMedGoogle Scholar
  • 20 Griffin C A, Hruban R H, Long P P. et al . Chromosome abnormalities in meningeal neoplasms: do they correlate with histology?.  Cancer Genet Cytogenet . 1994;  78 46-52
    CrossrefPubMedGoogle Scholar
  • 21 Bolger G B, Stamberg J, Kirsch I R, Hollis G F, Schwarz D F, Thomas G H. Chromosome translocation t(14;22) and oncogene (c-sis) variant in a pedigree with familial meningioma.  N Engl J Med . 1985;  312 564-567
    PubMedGoogle Scholar
  • 22 Awad I A, Kalfas I, Hahn J F, Little J R. Intracranial meningiomas in the aged: surgical outcome in the era of computed tomography.  Neurosurgery . 1989;  24 557-560
    PubMedGoogle Scholar
  • 23 Cogen P H, Daneshvar L, Bowcock A M, Metzger A K, Cavalli-Sforza L L. Loss of heterozygosity for chromosome 22 DNA sequences in human meningioma.  Cancer Genet Cytogenet . 1991;  53 271-277
    CrossrefPubMedGoogle Scholar
  • 24 Casalone R, Minelli E, Granata P, Giudici A. Pseudodicentric isochromosome(22) in meningiomas.  Cancer Genet Cytogenet . 1990;  45 273-275
    CrossrefPubMedGoogle Scholar
  • 25 Dumanski J P, Carlbom E, Collins V P, Nordenskjold M. Deletion mapping of a locus on human chromosome 22 involved in the oncogenesis of meningioma.  Proc Natl Acad Sci U S A . 1987;  84 9275-9279
    PubMedGoogle Scholar
  • 26 Lekanne Deprez H R, Riegman P H, van Drunen E. et al . Cytogenetic, molecular genetic and pathological analyses in 126 meningiomas.  J Neuropathol Exp Neurol . 1995;  54 224-235
    PubMedGoogle Scholar
  • 27 Meese E, Blin N, Zang K D. Loss of heterozygosity and the origin of meningioma.  Hum Genet . 1987;  77 349-351
    PubMedGoogle Scholar
  • 28 Seizinger B R, de la Monte S, Atkins L, Gusella J F, Martuza R L. Molecular genetic approach to human meningioma: loss of genes on chromosome 22.  Proc Natl Acad Sci U S A . 1987;  84 5419-5423
    PubMedGoogle Scholar
  • 29 Zang K D, Singer H. Chromosomal constitution of meningiomas.  Nature . 1967;  216 84-85
    PubMedGoogle Scholar
  • 30 Zankl H, Zang K D. Correlations between clinical and cytogenetical data in 180 human meningiomas.  Cancer Genet Cytogenet . 1980;  1 351-356
    CrossrefPubMedGoogle Scholar
  • 31 Zang K D. Meningioma: a cytogenetic model of a complex benign human tumor, including data on 394 karyotyped cases.  Cytogenet Cell Genet . 2001;  93 207-220
    CrossrefPubMedGoogle Scholar
  • 32 Lekanne Deprez H R, Bianchi A B, Groen N A. et al . Frequent NF2 gene transcript mutations in sporadic meningiomas and vestibular schwannomas.  Am J Hum Genet . 1994;  54 1022-1029
    PubMedGoogle Scholar
  • 33 Leon S P, Zhu J, Black P M. Genetic aberrations in human brain tumors.  Neurosurgery . 1994;  34 708-722
    PubMedGoogle Scholar
  • 34 Bigner S H, Mark J, Bigner D D. Cytogenetics of human brain tumors.  Cancer Genet Cytogenet . 1990;  47 141-154
    CrossrefPubMedGoogle Scholar
  • 35 Wolff R K, Frazer K A, Jackler R K, Lanser M J, Pitts L H, Cox D R. Analysis of chromosome 22 deletions in neurofibromatosis type 2-related tumors.  Am J Hum Genet . 1992;  51 478-485
    PubMedGoogle Scholar
  • 36 Merel P, Hoang-Xuan K, Sanson M. et al . Predominant occurrence of somatic mutations of the NF2 gene in meningiomas and schwannomas.  Genes Chromosomes Cancer . 1995;  13 211-216
    PubMedGoogle Scholar
  • 37 Papi L, De Vitis R L, Vitelli F. et al . Somatic mutations in the neurofibromatosis type 2 gene in sporadic meningiomas.  Hum Genet . 1995;  95 347-351
    PubMedGoogle Scholar
  • 38 Ng H K, Lau K M, Tse J Y. et al . Combined molecular genetic studies of chromosome 22q and the neurofibromatosis type 2 gene in central nervous system tumors.  Neurosurgery . 1995;  37 764-773
    PubMedGoogle Scholar
  • 39 Wellenreuther R, Kraus J A, Lenartz D. et al . Analysis of the neurofibromatosis 2 gene reveals molecular variants of meningioma.  Am J Pathol . 1995;  146 827-832
    PubMedGoogle Scholar
  • 40 Ikeda K, Saeki Y, Gonzalez-Agosti C, Ramesh V, Chiocca E A. Inhibition of NF2-negative and NF2-positive primary human meningioma cell proliferation by overexpression of merlin due to vector-mediated gene transfer.  J Neurosurg . 1999;  91 85-92
    PubMedGoogle Scholar
  • 41 Dirven C M, Grill J, Lamfers M L. et al . Gene therapy for meningioma: improved gene delivery with targeted adenoviruses.  J Neurosurg . 2002;  97 441-449
    PubMedGoogle Scholar
  • 42 Lee J H, Sundaram V, Stein D J, Kinney S E, Stacey D W, Golubi M. Reduced expression of schwannomin/merlin in human sporadic meningiomas.  Neurosurgery . 1997;  40 578-587
    PubMedGoogle Scholar
  • 43 Kalamarides M, Niwa-Kawakita M, Leblois H. et al . Nf2 gene inactivation in arachnoidal cells is rate-limiting for meningioma development in the mouse.  Genes Dev . 2002;  16 1060-1065
    CrossrefPubMedGoogle Scholar
  • 44 Akagi K, Kurahashi H, Arita N. et al . Deletion mapping of the long arm of chromosome 22 in human meningiomas.  Int J Cancer . 1995;  60 178-182
    PubMedGoogle Scholar
  • 45 Lekanne Deprez H R, Groen N A, van Biezen A N. et al . A t(4;22) in a meningioma points to the localization of a putative tumor-suppressor gene.  Am J Hum Genet . 1991;  48 783-790
    PubMedGoogle Scholar
  • 46 Lekanne Deprez H R, Groen N A, Louz D. et al . Constitutional DNA-level aberrations in chromosome 22 in a patient with multiple meningiomas.  Genes Chromosomes Cancer . 1994;  9 124-128
    PubMedGoogle Scholar
  • 47 Dumanski J P, Rouleau G A, Nordenskjold M, Collins V P. Molecular genetic analysis of chromosome 22 in 81 cases of meningioma.  Cancer Res . 1990;  50 5863-5867
    PubMedGoogle Scholar
  • 48 Pulst S M, Rouleau G A, Marineau C, Fain P, Sieb J P. Familial meningioma is not allelic to neurofibromatosis 2.  Neurology . 1993;  43 2096-2098
    PubMedGoogle Scholar
  • 49 Schneider G, Lutz S, Henn W, Zang K D, Blin N. Search for putative suppressor genes in meningioma: significance of chromosome 22.  Hum Genet . 1992;  88 579-582
    PubMedGoogle Scholar
  • 50 Ruttledge M H, Sarrazin J, Rangaratnam S. et al . Evidence for the complete inactivation of the NF2 gene in the majority of sporadic meningiomas.  Nat Genet . 1994;  6 180-184
    PubMedGoogle Scholar
  • 51 Ruttledge M H, Xie Y G, Han F Y. et al . Deletions on chromosome 22 in sporadic meningioma.  Genes Chromosomes Cancer . 1994;  10 122-130
    PubMedGoogle Scholar
  • 52 Bello M J, de Campos M J, Kusak M E. et al . Allelic loss at 1p is associated with tumor progression of meningiomas.  Genes Chromosomes Cancer . 1994;  9 296-298
    PubMedGoogle Scholar
  • 53 Steudel W I, Feld R, Henn W, Zang K D. Correlation between cytogenetic and clinical findings in 215 human meningiomas.  Arch Neurochir Suppl (Wien) . 1996;  65 73-76
    PubMedGoogle Scholar
  • 54 Muller P, Henn W, Niedermayer I. et al . Deletion of chromosome 1p and loss of expression of alkaline phosphatase indicate progression of meningiomas.  Clin Cancer Res . 1999;  5 3569-3577
    PubMedGoogle Scholar
  • 55 Henn W, Cremerius U, Heide G. et al . Monosomy 1p is correlated with enhanced in vivo glucose metabolism in meningiomas.  Cancer Genet Cytogenet . 1995;  79 144-148
    CrossrefPubMedGoogle Scholar
  • 56 Ketter R, Henn W, Niedermayer I. et al . Predictive value of progression-associated chromosomal aberrations for the prognosis of meningiomas: a retrospective study of 198 cases.  J Neurosurg . 2001;  95 601-607
    CrossrefPubMedGoogle Scholar
  • 57 Cai D X, Banerjee R, Scheithauer B W, Lohse C M, Kleinschmidt-Demasters B K, Perry A. Chromosome 1p and 14q FISH analysis in clinicopathologic subsets of meningioma: diagnostic and prognostic implications.  J Neuropathol Exp Neurol . 2001;  60 628-636
    PubMedGoogle Scholar
  • 58 Lopez-Gines C, Cerda-Nicolas M, Gil-Benso R, Barcia-Salorio J L, Llombart-Bosch A. Loss of 1p in recurrent meningiomas. A comparative study in successive recurrences by cytogenetics and fluorescence in situ hybridization.  Cancer Genet Cytogenet . 2001;  125 119-124
    CrossrefPubMedGoogle Scholar
  • 59 Simon M, von Deimling A, Larson J J. et al . Allelic losses on chromosomes 14, 10, and 1 in atypical and malignant meningiomas: a genetic model of meningioma progression.  Cancer Res . 1995;  55 4696-4701
    PubMedGoogle Scholar
  • 60 Schneider B F, Shashi V, von Kap-herr C, Golden W L. Loss of chromosomes 22 and 14 in the malignant progression of meningiomas. A comparative study of fluorescence in situ hybridization (FISH) and standard cytogenetic analysis.  Cancer Genet Cytogenet . 1995;  85 101-104
    CrossrefPubMedGoogle Scholar
  • 61 Perry A, Cai D X, Scheithauer B W. et al . Merlin, DAL-1, and progesterone receptor expression in clinicopathologic subsets of meningioma: a correlative immunohistochemical study of 175 cases.  J Neuropathol Exp Neurol . 2000;  59 872-879
    PubMedGoogle Scholar
  • 62 Gutmann D H, Donahoe J, Perry A. et al . Loss of DAL-1, a protein 4.1-related tumor suppressor, is an important early event in the pathogenesis of meningiomas.  Hum Mol Genet . 2000;  9 1495-1500
    CrossrefPubMedGoogle Scholar
  • 63 Prempree T, Amornmarn R, Faillace W J, Arce C A, Nguyen T Q. 1;19 translocation in human meningioma.  Cancer . 1993;  71 2306-2311
    PubMedGoogle Scholar
  • 64 Vagner Capodano M A, Grisoli F, Gambarelli D, Sedan R, Pellet W, De Victor B. Correlation between cytogenetic and histopathological findings in 75 human meningiomas.  Neurosurgery . 1993;  32 892-900
    PubMedGoogle Scholar
  • 65 Al Saadi A, Latimer F, Madercic M, Robbins T. Cytogenetic studies of human brain tumors and their clinical significance. II. Meningioma.  Cancer Genet Cytogenet . 1987;  26 127-141
    CrossrefPubMedGoogle Scholar
  • 66 Katsuyama J, Papenhausen P R, Herz F, Gazivoda P, Hirano A, Koss L G. Chromosome abnormalities in meningiomas.  Cancer Genet Cytogenet . 1986;  22 63-68
    CrossrefPubMedGoogle Scholar
  • 67 Westphal M, Hansel M, Kunzmann R, Holzel F, Herrmann H D. Spectrum of karyotypic aberrations in cultured human meningiomas.  Cytogenet Cell Genet . 1989;  52 45-49
    PubMedGoogle Scholar
  • 68 Bigner S H, Wong A J, Mark J. et al . Relationship between gene amplification and chromosomal deviations in malignant human gliomas.  Cancer Genet Cytogenet . 1987;  29 165-170
    CrossrefPubMedGoogle Scholar
  • 69 Mark J. Chromosomal abnormalities and their specificity in human neoplasms: an assessment of recent observations by banding techniques.  Adv Cancer Res . 1977;  24 165-222
    PubMedGoogle Scholar
  • 70 Lopez-Gines C, Cerda-Nicolas M, Barcia-Salorio J L, Llombart-Bosch A. Cytogenetical findings of recurrent meningiomas. A study of 10 tumors.  Cancer Genet Cytogenet . 1995;  85 113-117
    CrossrefPubMedGoogle Scholar
  • 71 Pykett M J, Murphy M, Harnish P R, George D L. Identification of a microsatellite instability phenotype in meningiomas.  Cancer Res . 1994;  54 6340-6343
    PubMedGoogle Scholar
  • 72 Cushing J, Eisenhardt L. Meningiomas arising from the tuberculum sella.  Arch Ophthalmol . 1929;  1 1-41
    PubMedGoogle Scholar
  • 73 Bickerstaff E R, Small J M, Guest I A. The relapsing course of certain meningiomas in relation to pregnancy and menstruation.  J Neurochem . 1958;  21 89-91
    CrossrefPubMedGoogle Scholar
  • 74 Goldstein P J, Rosenberg S, Smith R W. Maternal death and brain tumor: case report.  Am J Obstet Gynecol . 1972;  112 297-298
    PubMedGoogle Scholar
  • 75 Hagedoorne A. The chiasmal syndrome and retrobulbar neuritis in pregnancy.  Am J Ophthalmol . 1937;  20 690-699
    PubMedGoogle Scholar
  • 76 Weyand A S, Villemure J, Kelly P A. Regulation of DNA synthesis and growth of cells derived from primary human meningiomas.  Cancer Res . 1986;  46 2545-2550
    PubMedGoogle Scholar
  • 77 Mehta D, Khatib R, Patel S. Carcinoma of the breast and meningioma. Association and management.  Cancer . 1983;  51 1937-1940
    PubMedGoogle Scholar
  • 78 Schoenberg B S, Christine B W, Whisnant J P. Nervous system neoplasms and primary malignancies of other sites. The unique association between meningiomas and breast cancer.  Neurology . 1975;  25 705-712
    PubMedGoogle Scholar
  • 79 Bellur S N, Chandra V, Anderson R J. Association of meningiomas with obesity.  Ann Neurol . 1983;  13 346-347
    CrossrefPubMedGoogle Scholar
  • 80 Donnell M S, Meyer G A, Donegan W L. Estrogen-receptor protein in intracranial meningiomas.  J Neurosurg . 1979;  50 499-502
    PubMedGoogle Scholar
  • 81 Magdelenat H, Pertuiset B F, Poisson M. et al . Progestin and oestrogen receptors in meningiomas. Biochemical characterization, clinical and pathological correlations in 42 cases.  Acta Neurochir (Wien) . 1982;  64 199-213
    CrossrefPubMedGoogle Scholar
  • 82 Martuza R L, Miller D C, MacLaughlin D T. Estrogen and progestin binding by cytosolic and nuclear fractions of human meningiomas.  J Neurosurg . 1985;  62 750-756
    PubMedGoogle Scholar
  • 83 Poisson M. Sex steroid receptors in human meningiomas.  Clin Neuropharmacol . 1984;  7 320-324
    PubMedGoogle Scholar
  • 84 Tilzer L L, Plapp F V, Evans J P, Stone D, Alward K. Steroid receptor proteins in human meningiomas.  Cancer . 1982;  49 633-636
    PubMedGoogle Scholar
  • 85 Markwalder T M, Zava D T, Goldhirsch A, Markwalder R V. Estrogen and progesterone receptors in meningiomas in relation to clinical and pathologic features.  Surg Neurol . 1983;  20 42-47
    PubMedGoogle Scholar
  • 86 Piantelli M, Rinelli A, Macri E. et al . Type II estrogen binding sites and antiproliferative activity of quercetin in human meningiomas.  Cancer . 1993;  71 193-198
    PubMedGoogle Scholar
  • 87 Blankenstein M A, Blaauw G, Lamberts S W. Progestin and estrogen receptors in human meningioma.  Clin Neuropharmacol . 1984;  7 363-367
    PubMedGoogle Scholar
  • 88 Moguilewsky M, Pertuiset B F, Verzat C, Philibert D, Philippon J, Poisson M. Cytosolic and nuclear sex steroid receptors in meningioma.  Clin Neuropharmacol . 1984;  7 375-381
    PubMedGoogle Scholar
  • 89 Hayward E, Whitwell H, Paul K S, Barnes D M. Steroid receptors in human meningioma.  Clin Neuropharmacol . 1984;  7 351-356
    PubMedGoogle Scholar
  • 90 Cahill D W, Bashirelahi N, Solomon L W, Dalton T, Salcman M, Ducker T B. Estrogen and progesterone receptors in meningiomas.  J Neurosurg . 1984;  60 985-993
    PubMedGoogle Scholar
  • 91 Courriere P, Tremoulet M, Eche N, Armand J P. Hormonal steroid receptors in intracranial tumours and their relevance in hormone therapy.  Eur J Cancer Clin Oncol . 1985;  21 711-714
    CrossrefPubMedGoogle Scholar
  • 92 Blaauw G, Blankenstein M A, Lamberts S W. Sex steroid receptors in human meningiomas.  Acta Neurochir (Wien) . 1986;  79 42-47
    CrossrefPubMedGoogle Scholar
  • 93 Blankenstein M A, van der Meulen-Dijk C, Thijssen J H. Assay of oestrogen and progestin receptors in human meningioma cytosols using immunological methods.  Clin Chim Acta . 1987;  165 189-195
    CrossrefPubMedGoogle Scholar
  • 94 Benzel E C, Gelder F B. Correlation between sex hormone binding and peritumoral edema in intracranial meningiomas.  Neurosurgery . 1988;  23 169-174
    PubMedGoogle Scholar
  • 95 Koehorst S G, Jacobs H M, Tilanus M G, Bouwens A G, Thijssen J H, Blankenstein M A. Aberrant oestrogen receptor species in human meningioma tissue.  J Steroid Biochem Mol Biol . 1992;  43 57-61
    CrossrefPubMedGoogle Scholar
  • 96 Brandis A, Mirzai S, Tatagiba M, Walter G F, Samii M, Ostertag H. Immunohistochemical detection of female sex hormone receptors in meningiomas: correlation with clinical and histological features.  Neurosurgery . 1993;  33 212-218
    CrossrefPubMedGoogle Scholar
  • 97 Carroll R S, Glowacka D, Dashner K, Black P M. Progesterone receptor expression in meningiomas.  Cancer Res . 1993;  53 1312-1316
    PubMedGoogle Scholar
  • 98 Ironside J W, Battersby R D, Dangerfield V J, Parsons M A, Timperley W R, Underwood J C. Cryostat section assay of oestrogen and progesterone receptors in meningiomas: a clinicopathological study.  J Clin Pathol . 1986;  39 44-50
    PubMedGoogle Scholar
  • 99 Lesch K P, Fahlbusch R. Simultaneous estradiol and progesterone receptor analysis in meningiomas.  Surg Neurol . 1986;  26 257-263
    PubMedGoogle Scholar
  • 100 Lesch K P, Engl H G, Gross S. Androgen receptor binding activity in meningiomas.  Surg Neurol . 1987;  28 176-180
    PubMedGoogle Scholar
  • 101 Lesch K P, Engl H G, Schott W, Gross S. Immunoreactive estrogen receptor protein in meningiomas: comparison with the androgen receptor and progesterone receptor binding activity.  Zentralbl Neurochir . 1987;  48 124-134
    PubMedGoogle Scholar
  • 102 Schrell U M, Adams E F, Fahlbusch R. et al . Hormonal dependency of cerebral meningiomas. Part 1: Female sex steroid receptors and their significance as specific markers for adjuvant medical therapy.  J Neurosurg . 1990;  73 743-749
    PubMedGoogle Scholar
  • 103 Piquer J, Cerda M, Lluch A, Barcia-Salorio J L, Garcia-Conde J. Correlations of female steroid hormone receptors with histologic features in meningiomas.  Acta Neurochir (Wien) . 1991;  110 38-43
    CrossrefPubMedGoogle Scholar
  • 104 Meixensberger J, Caffier H, Naumann M, Hofmann E. Sex hormone binding and peritumoural oedema in meningiomas: is there a correlation?.  Acta Neurochir (Wien) . 1992;  115 98-102
    CrossrefPubMedGoogle Scholar
  • 105 Perrot-Applanat M, Groyer-Picard M T, Kujas M. Immunocytochemical study of progesterone receptor in human meningioma.  Acta Neurochir (Wien) . 1992;  115 20-30
    CrossrefPubMedGoogle Scholar
  • 106 Maxwell M, Galanopoulos T, Neville-Golden J, Antoniades H N. Expression of androgen and progesterone receptors in primary human meningiomas.  J Neurosurg . 1993;  78 456-462
    PubMedGoogle Scholar
  • 107 Verhagen A, Go K G, Visser G M, Blankenstein M A, Vaalburg W. The presence of progesterone receptors in arachnoid granulations and in the lining of arachnoid cysts: its relevance to expression of progesterone receptors in meningiomas.  Br J Neurosurg . 1995;  9 47-50
    CrossrefPubMedGoogle Scholar
  • 108 Bouillot P, Pellissier J F, Devictor B. et al . Quantitative imaging of estrogen and progesterone receptors, estrogen-regulated protein, and growth fraction: immunocytochemical assays in 52 meningiomas. Correlation with clinical and morphological data.  J Neurosurg . 1994;  81 765-773
    PubMedGoogle Scholar
  • 109 Zava D T, Markwalder T M, Markwalder R V. Biological expression of steroid hormone receptors in primary meningioma cells in monolayer culture.  Clin Neuropharmacol . 1984;  7 382-388
    PubMedGoogle Scholar
  • 110 Jay J R, MacLaughlin D T, Riley K R, Martuza R L. Modulation of meningioma cell growth by sex steroid hormones in vitro.  J Neurosurg . 1985;  62 757-762
    PubMedGoogle Scholar
  • 111 Olson J J, Beck D W, Schlechte J, Loh P M. Hormonal manipulation of meningiomas in vitro.  J Neurosurg . 1986;  65 99-107
    PubMedGoogle Scholar
  • 112 Weisman A S, Villemure J G, Kelly P A. Regulation of DNA synthesis and growth of cells derived from primary human meningiomas.  Cancer Res . 1986;  46 2545-2550
    PubMedGoogle Scholar
  • 113 Waelti E R, Markwalder T M. Endocrine manipulation of meningiomas with medroxyprogesterone acetate. Effect of MPA on growth of primary meningioma cells in monolayer tissue culture.  Surg Neurol . 1989;  31 96-100
    PubMedGoogle Scholar
  • 114 Grunberg S M, Daniels A M, Muensch H. et al . Correlation of meningioma hormone receptor status with hormone sensitivity in a tumor stem-cell assay.  J Neurosurg . 1987;  66 405-408
    PubMedGoogle Scholar
  • 115 Adams E F, Schrell U M, Fahlbusch R, Thierauf P. Hormonal dependency of cerebral meningiomas. Part 2: In vitro effect of steroids, bromocriptine, and epidermal growth factor on growth of meningiomas.  J Neurosurg . 1990;  73 750-755
    PubMedGoogle Scholar
  • 116 Olson J J, Beck D W, Schlechte J A, Loh P M. Effect of the antiprogesterone RU-38486 on meningioma implanted into nude mice.  J Neurosurg . 1987;  66 584-587
    PubMedGoogle Scholar
  • 117 Koper J W, Foekens J A, Braakman R, Lamberts S W. Effects of progesterone on the response to epidermal growth factor and other growth factors in cultured human meningioma cells.  Cancer Res . 1990;  50 2604-2607
    PubMedGoogle Scholar
  • 118 Schrell U M, Nomikos P, Schrauzer T. et al . Hormonal dependency of cerebral meningiomas.  Acta Neurochir Suppl (Wien) . 1996;  65 54-57
    PubMedGoogle Scholar
  • 119 Markwalder T M, Seiler R W. Chronic subdural hematomas: to drain or not to drain?.  Neurosurgery . 1985;  16 185-188
    PubMedGoogle Scholar
  • 120 Goodwin J W, Crowley J, Eyre H J, Stafford B, Jaeckle K A, Townsend J J. A phase II evaluation of tamoxifen in unresectable or refractory meningiomas: a Southwest Oncology Group study.  J Neurooncol . 1993;  15 75-77
    CrossrefPubMedGoogle Scholar
  • 121 Markwalder T M, Gerber H A, Waelti E, Schaffner T, Markwalder R V. Hormonotherapy of meningiomas with medroxyprogesterone acetate. Immunohistochemical demonstration of the effect of medroxyprogesterone acetate on growth fractions of meningioma cells using the monoclonal antibody Ki-67.  Surg Neurol . 1988;  30 97-101
    PubMedGoogle Scholar
  • 122 Jaaskelainen J, Laasonen E, Karkkainen J, Haltia M, Troupp H. Hormone treatment of meningiomas: lack of response to medroxyprogesterone acetate (MPA). A pilot study of five cases.  Acta Neurochir (Wien) . 1986;  80 35-41
    CrossrefPubMedGoogle Scholar
  • 123 Grunberg S M, Weiss M H. Lack of efficacy of megestrol acetate in the treatment of unresectable meningioma.  J Neurooncol . 1990;  8 61-65
    PubMedGoogle Scholar
  • 124 Grunberg S M, Weiss M H, Spitz I M. et al . Treatment of unresectable meningiomas with the antiprogesterone agent mifepristone.  J Neurosurg . 1991;  74 861-866
    CrossrefPubMedGoogle Scholar
  • 125 Lamberts S W, Koper J W, de Jong H F. The endocrine effects of long-term treatment with mifepristone (RU 486).  J Clin Endocrinol Metab . 1991;  73 187-191
    PubMedGoogle Scholar
  • 126 Lamberts S W, Koper J W, Reubi J C, Krenning E P. Endocrine aspects of the diagnosis and treatment of primary brain tumours.  Clin Endocrinol (Oxf) . 1992;  37 1-10
    PubMedGoogle Scholar
  • 127 Sartor O, Figg W D. Mifepristone: antineoplastic studies.  Clin Obstet Gynecol . 1996;  39 498-505
    CrossrefPubMedGoogle Scholar
  • 128 Piper J G, Follett K A, Fantin A. Sphenoid wing meningioma progression after placement of a subcutaneous progesterone agonist contraceptive implant.  Neurosurgery . 1994;  34 723-725
    PubMedGoogle Scholar
  • 129 Matsuda Y, Kawamoto K, Kiya K, Kurisu K, Sugiyama K, Uozumi T. Antitumor effects of antiprogesterones on human meningioma cells in vitro and in vivo.  J Neurosurg . 1994;  80 527-534
    PubMedGoogle Scholar
  • 130 Davis C. Surgical and non-surgical treatment of symptomatic intracranial meningiomas.  Br J Neurosurg . 1995;  9 295-302
    CrossrefPubMedGoogle Scholar
  • 131 Carroll R S, Schrell U M, Zhang J. et al . Dopamine D1, dopamine D2, and prolactin receptor messenger ribonucleic acid expression by the polymerase chain reaction in human meningiomas.  Neurosurgery . 1996;  38 367-375
    PubMedGoogle Scholar
  • 132 Jimenez-Hakim E, el Azouzi M, Black P M. The effect of prolactin and bombesin on the growth of meningioma-derived cells in monolayer culture.  J Neurooncol . 1993;  16 185-190
    CrossrefPubMedGoogle Scholar
  • 133 Boyle-Walsh E, Shenkin A, White M C, Fraser W D. Effect of glycoprotein and protein hormones on human meningioma cell proliferation in vitro.  J Endocrinol . 1995;  145 155-161
    PubMedGoogle Scholar
  • 134 Smidt M, Kirsch I, Ratner L. Deletion of Alu sequences in the fifth c-sis intron in individuals with meningiomas.  J Clin Invest . 1990;  86 1151-1157
    PubMedGoogle Scholar
  • 135 Kazumoto K, Tamura M, Hoshino H, Yuasa Y. Enhanced expression of the sis and c-myc oncogenes in human meningiomas.  J Neurosurg . 1990;  72 786-791
    PubMedGoogle Scholar
  • 136 Carstens C, Messe E, Zang K D, Blin N. Human KRAS oncogene expression in meningioma.  Cancer Lett . 1988;  43 37-41
    CrossrefPubMedGoogle Scholar
  • 137 Diedrich U, Eckermann O, Schmidtke J. Rare Ha-ras and c-mos alleles in patients with intracranial tumors.  Neurology . 1988;  38 587-589
    PubMedGoogle Scholar
  • 138 Detta A, Kenny B G, Smith C, Logan A, Hitchcock E. Correlation of proto-oncogene expression and proliferation and meningiomas.  Neurosurgery . 1993;  33 1065-1074
    PubMedGoogle Scholar
  • 139 Wang G L, Jiang B H, Rue E A, Semenza G L. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension.  Proc Natl Acad Sci USA . 1995;  92 5510-5514
    CrossrefPubMedGoogle Scholar
  • 140 Zhao J F, Sharma S. Expression of the ROS1 oncogene for tyrosine receptor kinase in adult human meningiomas.  Cancer Genet Cytogenet . 1995;  83 148-154
    CrossrefPubMedGoogle Scholar
  • 141 Baugnet-Mahieu L, Lemaire M, Brotchi J. et al . Epidermal growth factor receptors in human tumors of the central nervous system.  Anticancer Res . 1990;  10 1275-1280
    PubMedGoogle Scholar
  • 142 Grimaux M, Magdelenat H, Poisson M. et al . [EGF receptors (epidermal growth factor) and steroid receptors in human meningioma].  Rev Neurol (Paris) . 1988;  144 96-103
    PubMedGoogle Scholar
  • 143 Diedrich U, Lucius J, Baron E, Behnke J, Pabst B, Zoll B. Distribution of epidermal growth factor receptor gene amplification in brain tumours and correlation to prognosis.  J Neurol . 1995;  242 683-688
    PubMedGoogle Scholar
  • 144 Torp S H, Helseth E, Dalen A, Unsgaard G. Expression of epidermal growth factor receptor in human meningiomas and meningeal tissue.  APMIS . 1992;  100 797-802
    PubMedGoogle Scholar
  • 145 Sanfilippo J S, Rao C V, Guarnaschelli J J. et al . Detection of epidermal growth factor and transforming growth factor alpha protein in meningiomas and other tumors of the central nervous system in human beings.  Surg Gynecol Obstet . 1993;  177 488-496
    PubMedGoogle Scholar
  • 146 Linggood R M, Hsu D W, Efird J T, Pardo F S. TGF alpha expression in meningioma-tumor progression and therapeutic response.  J Neurooncol . 1995;  26 45-51
    CrossrefPubMedGoogle Scholar
  • 147 Westphal M, Herrmann H D. Epidermal growth factor-receptors on cultured human meningioma cells.  Acta Neurochir (Wien) . 1986;  83 62-66
    CrossrefPubMedGoogle Scholar
  • 148 Koper J W, Zwarthoff E C, Hagemeijer A. et al . Inhibition of the growth of cultured human meningioma cells by recombinant interferon-alpha.  Eur J Cancer . 1991;  27 416-419
    PubMedGoogle Scholar
  • 149 Di Carlo A, Mariano A, Macchia P E, Moroni M C, Beguinot L, Macchia V. Epidermal growth factor receptor in human brain tumors.  J Endocrinol Invest . 1992;  15 31-37
    PubMedGoogle Scholar
  • 150 Kitagawa N, Tsutsumi K, Niwa M. et al . Expression of a functional endothelin (ETA) receptor in human meningiomas.  J Neurosurg . 1994;  80 723-731
    PubMedGoogle Scholar
  • 151 Johnson M D, Horiba M, Winnier A R, Arteaga C L. The epidermal growth factor receptor is associated with phospholipase C-gamma 1 in meningiomas.  Hum Pathol . 1994;  25 146-153
    CrossrefPubMedGoogle Scholar
  • 152 Todo T, Fahlbusch R. Accumulation of inositol phosphates in low-passage human meningioma cells following treatment with epidermal growth factor.  J Neurosurg . 1994;  80 890-896
    PubMedGoogle Scholar
  • 153 Carroll R S, Black P M, Zhang J. et al . Expression and activation of epidermal growth factor receptors in meningiomas.  J Neurosurg . 1997;  87 315-323
    PubMedGoogle Scholar
  • 154 Wang J L, Nister M, Hermansson M, Westermark B, Ponten J. Expression of PDGF beta-receptors in human meningioma cells.  Int J Cancer . 1990;  46 772-778
    PubMedGoogle Scholar
  • 155 Adams E F, Todo T, Schrell U M, Thierauf P, White M C, Fahlbusch R. Autocrine control of human meningioma proliferation: secretion of platelet-derived growth-factor-like molecules.  Int J Cancer . 1991;  49 398-402
    PubMedGoogle Scholar
  • 156 Black P M, Carroll R, Glowacka D, Riley K, Dashner K. Platelet-derived growth factor expression and stimulation in human meningiomas.  J Neurosurg . 1994;  81 388-393
    PubMedGoogle Scholar
  • 157 Johnson M D, Woodard A, Kim P, Frexes-Steed M. Evidence for mitogen-associated protein kinase activation and transduction of mitogenic signals by platelet-derived growth factor in human meningioma cells.  J Neurosurg . 2001;  94 293-300
    CrossrefPubMedGoogle Scholar
  • 158 Figarella-Branger D, Vagner-Capodano A M, Bouillot P. et al . Platelet-derived growth factor (PDGF) and receptor (PDGFR) expression in human meningiomas: correlations with clinicopathological features and cytogenetic analysis.  Neuropathol Appl Neurobiol . 1994;  20 439-447
    PubMedGoogle Scholar
  • 159 Maxwell M, Galanopoulos T, Hedley-Whyte E T, Black P M, Antoniades H N. Human meningiomas co-express platelet-derived growth factor (PDGF) and PDGF-receptor genes and their protein products.  Int J Cancer . 1990;  46 16-21
    PubMedGoogle Scholar
  • 160 Todo T, Adams E F, Fahlbusch R, Dingermann T, Werner H. Autocrine growth stimulation of human meningioma cells by platelet-derived growth factor.  J Neurosurg . 1996;  84 852-859
    PubMedGoogle Scholar
  • 161 Schrell U M, Gauer S, Kiesewetter F. et al . Inhibition of proliferation of human cerebral meningioma cells by suramin: effects on cell growth, cell cycle phases, extracellular growth factors, and PDGF-BB autocrine growth loop.  J Neurosurg . 1995;  82 600-607
    PubMedGoogle Scholar
  • 162 Todo T, Adams E F, Fahlbusch R. Inhibitory effect of trapidil on human meningioma cell proliferation via interruption of autocrine growth stimulation.  J Neurosurg . 1993;  78 463-469
    PubMedGoogle Scholar
  • 163 Jensen R L, Lee Y S, Guijrati M, Origitano T C, Wurster R D, Reichman O H. Inhibition of in vitro meningioma proliferation after growth factor stimulation by calcium channel antagonists: Part II. Additional growth factors, growth factor receptor immunohistochemistry, and intracellular calcium measurements.  Neurosurgery . 1995;  37 937-947
    PubMedGoogle Scholar
  • 164 Jensen R L, Origitano T C, Lee Y S, Weber M, Wurster R D. In vitro growth inhibition of growth factor-stimulated meningioma cells by calcium channel antagonists.  Neurosurgery . 1995;  36 365-437
    PubMedGoogle Scholar
  • 165 Jensen R L, Petr M, Wurster R D. Calcium channel antagonist effect on in vitro meningioma signal transduction pathways after growth factor stimulation.  Neurosurgery . 2000;  46 692-703
    PubMedGoogle Scholar
  • 166 Merry S, Fetherston C A, Kaye S B, Freshney R I, Plumb J A. Resistance of human glioma to adriamycin in vitro: the role of membrane transport and its circumvention with verapamil.  Br J Cancer . 1986;  53 129-135
    PubMedGoogle Scholar
  • 167 Jensen R L, Wurster R D. Calcium channel antagonists inhibit growth of subcutaneous xenograft meningiomas in nude mice.  Surg Neurol . 2001;  55 275-283
    PubMedGoogle Scholar
  • 168 Bowles A P, Pantazis C G, Wansley W. Use of verapamil to enhance the antiproliferative activity of BCNU in human glioma cells: an in vitro and in vivo study.  J Neurosurg . 1990;  73 248-253
    PubMedGoogle Scholar
  • 169 Cano-Gauci D F, Riordan J R. Action of calcium antagonists on multidrug resistant cells. Specific cytotoxicity independent of increased cancer drug accumulation.  Biochem Pharmacol . 1987;  36 2115-2123
    CrossrefPubMedGoogle Scholar
  • 170 Helson L. Calcium channel blocker enhancement of anticancer drug cytotoxicity-a review.  Cancer Drug Deliv . 1984;  1 353-361
    PubMedGoogle Scholar
  • 171 Ince P, Appleton D R, Finney K J, Sunter J P, Watson A J. Verapamil increases the sensitivity of primary human colorectal carcinoma tissue to vincristine.  Br J Cancer . 1986;  53 137-139
    PubMedGoogle Scholar
  • 172 Robinson B A, Clutterbuck R D, Millar J L, McElwain T J. Verapamil potentiation of melphalan cytotoxicity and cellular uptake in murine fibrosarcoma and bone marrow.  Br J Cancer . 1985;  52 813-822
    PubMedGoogle Scholar
  • 173 Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil.  Cancer Res . 1981;  41 1967-1972
    PubMedGoogle Scholar
  • 174 Takahashi J A, Suzui H, Yasuda Y. et al . Gene expression of fibroblast growth factor receptors in the tissues of human gliomas and meningiomas.  Biochem Biophys Res Commun . 1991;  177 1-7
    CrossrefPubMedGoogle Scholar
  • 175 Takahashi J A, Mori H, Fukumoto M. et al . Gene expression of fibroblast growth factors in human gliomas and meningiomas: demonstration of cellular source of basic fibroblast growth factor mRNA and peptide in tumor tissues.  Proc Natl Acad Sci USA . 1990;  87 5710-5714
    PubMedGoogle Scholar
  • 176 Ueba T, Takahashi J A, Fukumoto M. et al . Expression of fibroblast growth factor receptor-1 in human glioma and meningioma tissues.  Neurosurgery . 1994;  34 221-226
    PubMedGoogle Scholar
  • 177 Paulus W, Grothe C, Sensenbrenner M. et al . Localization of basic fibroblast growth factor, a mitogen and angiogenic factor, in human brain tumors.  Acta Neuropathol (Berl) . 1990;  79 418-423
    CrossrefPubMedGoogle Scholar
  • 178 Brem S, Tsanaclis A M, Gately S, Gross J L, Herblin W F. Immunolocalization of basic fibroblast growth factor to the microvasculature of human brain tumors.  Cancer . 1992;  70 2673-2680
    PubMedGoogle Scholar
  • 179 Samoto K, Ikezaki K, Ono M. et al . Expression of vascular endothelial growth factor and its possible relation with neovascularization in human brain tumors.  Cancer Res . 1995;  55 1189-1193
    PubMedGoogle Scholar
  • 180 Antoniades H N, Galanopoulos T, Neville-Golden J, Maxwell M. Expression of insulin-like growth factors I and II and their receptor mRNAs in primary human astrocytomas and meningiomas; in vivo studies using in situ hybridization and immunocytochemistry.  Int J Cancer . 1992;  50 215-222
    PubMedGoogle Scholar
  • 181 Glick R P, Gettleman R, Patel K, Lakshman R, Tsibris J C. Insulin and insulin-like growth factor I in brain tumors: binding and in vitro effects.  Neurosurgery . 1989;  24 791-797
    PubMedGoogle Scholar
  • 182 Glick R P, Unterman T G, Van der Woude M, Blaydes L Z. Insulin and insulin-like growth factors in central nervous system tumors. Part V: Production of insulin-like growth factors I and II in vitro.  J Neurosurg . 1992;  77 445-450
    PubMedGoogle Scholar
  • 183 Lichtor T, Kurpakus M A, Gurney M E. Expression of insulin-like growth factors and their receptors in human meningiomas.  J Neurooncol . 1993;  17 183-190
    CrossrefPubMedGoogle Scholar
  • 184 Kurihara M, Tokunaga Y, Tsutsumi K. et al . Characterization of insulin-like growth factor I and epidermal growth factor receptors in meningioma.  J Neurosurg . 1989;  71 538-544
    PubMedGoogle Scholar
  • 185 Unterman T G, Glick R P, Waites G T, Bell S C. Production of insulin-like growth factor-binding proteins by human central nervous system tumors.  Cancer Res . 1991;  51 3030-3036
    PubMedGoogle Scholar
  • 186 Friend K E. Cancer and the potential place for growth hormone receptor antagonist therapy.  Growth Horm IGF Res . 2001;  11 (suppl A) S121-S123
    PubMedGoogle Scholar
  • 187 Tsutsumi K, Kitagawa N, Niwa M, Himeno A, Taniyama K, Shibata S. Effect of suramin on 125I-insulin-like growth factor-I binding to human meningiomas and on proliferation of meningioma cells.  J Neurosurg . 1994;  80 502-509
    PubMedGoogle Scholar
  • 188 Lawrence J H, Tobias C A, Linfoot J A. et al . Successful treatment of acromegaly: metabolic and clinical studies in 145 patients.  J Clin Endocrinol Metab . 1970;  31 180-198
    PubMedGoogle Scholar
  • 189 Khandwala H M, McCutcheon I E, Flyvbjerg A, Friend K E. The effects of insulin-like growth factors on tumorigenesis and neoplastic growth.  Endocr Rev . 2000;  21 215-244
    CrossrefPubMedGoogle Scholar
  • 190 McCutcheon I E, Flyvbjerg A, Hill H. et al . Antitumor activity of the growth hormone receptor antagonist pegvisomant against human meningiomas in nude mice.  J Neurosurg . 2001;  94 487-492
    PubMedGoogle Scholar
  • 191 Trainer P J, Drake W M, Katznelson L. et al . Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant.  N Engl J Med . 2000;  342 1171-1177
    CrossrefPubMedGoogle Scholar
  • 192 van der Lely J A, Hutson R K, Trainer P J. et al . Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist.  Lancet . 2001;  358 1754-1759
    CrossrefPubMedGoogle Scholar
  • 193 Garcia-Luna P P, Relimpio F, Pumar A. et al . Clinical use of octreotide in unresectable meningiomas. A report of three cases.  J Neurosurg Sci . 1993;  37 237-241
    PubMedGoogle Scholar
  • 194 Kunert-Radek J, Stepien H, Radek A, Lyson K, Pawlikowski M. Inhibitory effect of calcium channel blockers on proliferation of human glioma cells in vitro.  Acta Neurol Scand . 1989;  79 166-169
    PubMedGoogle Scholar
  • 195 Huisman T W, Tanghe H L, Koper J W. et al . Progesterone, oestradiol, somatostatin and epidermal growth factor receptors on human meningiomas and their CT characteristics.  Eur J Cancer . 1991;  27 1453-1457
    PubMedGoogle Scholar
  • 196 Reubi J C, Maurer R, von Werder K, Torhorst J, Klijn J G, Lamberts S W. Somatostatin receptors in human endocrine tumors.  Cancer Res . 1987;  47 551-558
    PubMedGoogle Scholar
  • 197 Reubi J C, Horisberger U, Lang W, Koper J W, Braakman R, Lamberts S W. Coincidence of EGF receptors and somatostatin receptors in meningiomas but inverse, differentiation-dependent relationship in glial tumors.  Am J Pathol . 1989;  134 337-344
    PubMedGoogle Scholar
  • 198 Schulz S, Pauli S U, Handel M, Dietzmann K, Firsching R, Hollt V. Immunohistochemical determination of five somatostatin receptors in meningioma reveals frequent overexpression of somatostatin receptor subtype sst2A.  Clin Cancer Res . 2000;  6 1865-1874
    PubMedGoogle Scholar
  • 199 Berkman R A, Merrill M J, Reinhold W C. et al . Expression of the vascular permeability factor/vascular endothelial growth factor gene in central nervous system neoplasms.  J Clin Invest . 1993;  91 153-159
    CrossrefPubMedGoogle Scholar
  • 200 Hatva E, Kaipainen A, Mentula P. et al . Expression of endothelial cell-specific receptor tyrosine kinases and growth factors in human brain tumors.  Am J Pathol . 1995;  146 368-378
    PubMedGoogle Scholar
  • 201 Takano S, Yoshii Y, Kondo S. et al . Concentration of vascular endothelial growth factor in the serum and tumor tissue of brain tumor patients.  Cancer Res . 1996;  56 2185-2190
    PubMedGoogle Scholar
  • 202 Goldman C K, Bharara S, Palmer C A. et al . Brain edema in meningiomas is associated with increased vascular endothelial growth factor expression.  Neurosurgery . 1997;  40 1269-1277
    PubMedGoogle Scholar
  • 203 Kalkanis S N, Carroll R S, Zhang J, Zamani A A, Black P M. Correlation of vascular endothelial growth factor messenger RNA expression with peritumoral vasogenic cerebral edema in meningiomas.  J Neurosurg . 1996;  85 1095-1101
    PubMedGoogle Scholar
  • 204 Provias J, Claffey K, delAguila L, Lau N, Feldkamp M, Guha A. Meningiomas: role of vascular endothelial growth factor/vascular permeability factor in angiogenesis and peritumoral edema.  Neurosurgery . 1997;  40 1016-1026
    PubMedGoogle Scholar
  • 205 Lamszus K, Lengler U, Schmidt N O, Stavrou D, Ergun S, Westphal M. Vascular endothelial growth factor, hepatocyte growth factor/scatter factor, basic fibroblast growth factor, and placenta growth factor in human meningiomas and their relation to angiogenesis and malignancy.  Neurosurgery . 2000;  46 938-948
    PubMedGoogle Scholar
  • 206 Shono T, Inamura T, Torisu M, Suzuki S O, Fukui M. Vascular endothelial growth factor and malignant transformation of a meningioma: case report.  Neurol Res . 2000;  22 189-193
    PubMedGoogle Scholar
  • 207 Dietzmann K, von Bossanyi P, Warich-Kirches M, Kirches E, Synowitz H J, Firsching R. Immunohistochemical detection of vascular growth factors in angiomatous and atypical meningiomas, as well as hemangiopericytomas.  Pathol Res Pract . 1997;  193 503-510
    PubMedGoogle Scholar
  • 208 Nishikawa R, Cheng S Y, Nagashima R, Huang H J, Cavenee W K, Matsutani M. Expression of vascular endothelial growth factor in human brain tumors.  Acta Neuropathol (Berl) . 1998;  96 453-462
    CrossrefPubMedGoogle Scholar
  • 209 Pietsch T, Valter M M, Wolf H K. et al . Expression and distribution of vascular endothelial growth factor protein in human brain tumors.  Acta Neuropathol (Berl) . 1997;  93 109-117
    CrossrefPubMedGoogle Scholar
  • 210 Yamasaki F, Yoshioka H, Hama S, Sugiyama K, Arita K, Kurisu K. Recurrence of meningiomas.  Cancer . 2000;  89 1102-1110
    CrossrefPubMedGoogle Scholar
  • 211 Bitzer M, Opitz H, Popp J. et al . Angiogenesis and brain oedema in intracranial meningiomas: influence of vascular endothelial growth factor.  Acta Neurochir (Wien) . 1998;  140 333-340
    CrossrefPubMedGoogle Scholar
  • 212 Yoshioka H, Hama S, Taniguchi E, Sugiyama K, Arita K, Kurisu K. Peritumoral brain edema associated with meningioma: influence of vascular endothelial growth factor expression and vascular blood supply.  Cancer . 1999;  85 936-944
    CrossrefPubMedGoogle Scholar
  • 213 Tsai J C, Hsiao Y Y, Teng L J. et al . Regulation of vascular endothelial growth factor secretion in human meningioma cells.  J Formos Med Assoc . 1999;  98 111-117
    PubMedGoogle Scholar
  • 214 Forsythe J A, Jiang B H, Iyer N V. et al . Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1.  Mol Cell Biol . 1996;  16 4604-4613
    PubMedGoogle Scholar
  • 215 Richard D E, Berra E, Pouyssegur J. Angiogenesis: how a tumor adapts to hypoxia.  Biochem Biophys Res Commun . 1999;  266 718-722
    CrossrefPubMedGoogle Scholar
  • 216 Jensen R L, Soleau S, Bhayani M K, Christiansen D. Expression of hypoxia inducible factor-1 alpha and correlation with preoperative embolization of meningiomas.  J Neurosurg . 2002;  97 658-667
    PubMedGoogle Scholar
  • 217 Pagotto U, Arzberger T, Hopfner U, Weindl A, Stalla G K. Cellular localization of endothelin receptor mRNAs (ETA and ETB) in brain tumors and normal human brain.  J Cardiovasc Pharmacol . 1995;  26 (suppl 3) S104-S106
    PubMedGoogle Scholar
  • 218 Pagotto U, Arzberger T, Hopfner U. et al . Expression and localization of endothelin-1 and endothelin receptors in human meningiomas. Evidence for a role in tumoral growth.  J Clin Invest . 1995;  96 2017-2025
    PubMedGoogle Scholar
  • 219 Harland S P, Kuc R E, Pickard J D, Davenport A P. Characterization of endothelin receptors in human brain cortex, gliomas, and meningiomas.  J Cardiovasc Pharmacol . 1995;  26 (suppl 3) S408-S411
    PubMedGoogle Scholar
  • 220 Yamaga S, Tsutsumi K, Niwa M. et al . Endothelin receptor in microvessels isolated from human meningiomas: quantification with radioluminography.  Cell Mol Neurobiol . 1995;  15 327-340
    PubMedGoogle Scholar
  • 221 Bek E L, McMillen M A. Endothelins are angiogenic.  J Cardiovasc Pharmacol . 2000;  36 S135-S139
    PubMedGoogle Scholar
  • 222 Harland S P, Kuc R E, Pickard J D, Davenport A P. Expression of endothelin(A) receptors in human gliomas and meningiomas, with high affinity for the selective antagonist PD156707.  Neurosurgery . 1998;  43 890-899
    PubMedGoogle Scholar
  • 223 Nitta T, Sato K, Okumura K. Transforming growth factor (TGF)-beta like activity of intracranial meningioma and its effect on cell growth.  J Neurol Sci . 1991;  101 19-23
    CrossrefPubMedGoogle Scholar
  • 224 Merlo A, Juretic A, Zuber M. et al . Cytokine gene expression in primary brain tumours, metastases and meningiomas suggests specific transcription patterns.  Eur J Cancer . 1993;  29A 2118-2125
    PubMedGoogle Scholar
  • 225 Johnson M D, Federspiel C F, Gold L I, Moses H L. Transforming growth factor-beta and transforming growth factor beta-receptor expression in human meningioma cells.  Am J Pathol . 1992;  141 633-642
    PubMedGoogle Scholar
  • 226 Johnson M D, Gold L I, Moses H L. Evidence for transforming growth factor-beta expression in human leptomeningeal cells and transforming growth factor-beta-like activity in human cerebrospinal fluid.  Lab Invest . 1992;  67 360-368
    PubMedGoogle Scholar
  • 227 Johnson M D, Jennings M T, Gold L I, Moses H L. Transforming growth factor-beta in neural embryogenesis and neoplasia.  Hum Pathol . 1993;  24 457-462
    CrossrefPubMedGoogle Scholar
  • 228 Reubi J C, Lamberts S W, Palacios J M. Hormone dependency of meningiomas.  Lancet . 1989;  2 1099-1100
    PubMedGoogle Scholar
  • 229 Schrell U M, Nomikos P, Fahlbusch R. Presence of dopamine D1 receptors and absence of dopamine D2 receptors in human cerebral meningioma tissue.  J Neurosurg . 1992;  77 288-294
    PubMedGoogle Scholar
  • 230 Todo T, Adams E F, Rafferty B, Fahlbusch R, Dingermann T, Werner H. Secretion of interleukin-6 by human meningioma cells: possible autocrine inhibitory regulation of neoplastic cell growth.  J Neurosurg . 1994;  81 394-401
    PubMedGoogle Scholar
  • 231 Levy E I, Paino J E, Sarin P S. et al . Enzyme-linked immunosorbent assay quantification of cytokine concentrations in human meningiomas.  Neurosurgery . 1996;  39 823-829
    PubMedGoogle Scholar
  • 232 Boyle-Walsh E, Hashim I A, Speirs V, Fraser W D, White M C. Interleukin-6 (IL-6) production and cell growth of cultured human ameningiomas: interactions with interleukin-1 beta (IL-1 beta) and interleukin-4 (IL-4) in vitro.  Neurosci Lett . 1994;  170 129-132
    CrossrefPubMedGoogle Scholar
  • 233 Huttner A, Lei T, Fahlbusch R, Schrell W, Adams E F. Relationship between cAMP induced inhibition of human meningioma cell proliferation and autocrine secretion of interleukin-6.  Life Sci . 1996;  58 1323-1329
    CrossrefPubMedGoogle Scholar
  • 234 Folkman J, Ingber D. Inhibition of angiogenesis.  Semin Cancer Biol . 1992;  3 89-96
    PubMedGoogle Scholar
  • 235 Kaba S E, DeMonte F, Bruner J M. et al . The treatment of recurrent unresectable and malignant meningiomas with interferon alpha-2B.  Neurosurgery . 1997;  40 271-275
    CrossrefPubMedGoogle Scholar
  • 236 Zhang Z J, Muhr C, Wang J L. Interferon-alpha inhibits the DNA synthesis induced by PDGF and EGF in cultured meningioma cells.  Anticancer Res. 16 717-723
    PubMedGoogle Scholar
  • 237 Wober-Bingol C, Wober C, Marosi C, Prayer D. Interferon-alfa-2b for meningioma.  Lancet . 1995;  345 331
    PubMedGoogle Scholar
  • 238 Muhr C, Gudjonsson O, Lilja A, Hartman M, Zhang Z J, Langstrom B. Meningioma treated with interferon-alpha, evaluated with [(11)C]-L-methionine positron emission tomography.  Clin Cancer Res . 2001;  7 2269-2276
    PubMedGoogle Scholar
  • 239 Gibelli N, Zibera C, Butti G. et al . Hormonal modulation of brain tumour growth: a cell culture study.  Acta Neurochir (Wien) . 1989;  101 129-133
    CrossrefPubMedGoogle Scholar
  • 240 Lee L S, Chi C W, Chang T J, Chou M D, Liu H C, Liu T Y. Steroid hormone receptors in meningiomas of Chinese patients.  Neurosurgery . 1989;  25 541-545
    PubMedGoogle Scholar
  • 241 Yu Z Y, Wrange O, Boethius J, Hatam A, Granholm L, Gustafsson J A. A study of glucocorticoid receptors in intracranial tumors.  J Neurosurg . 1981;  55 757-760
    PubMedGoogle Scholar
  • 242 Carroll R S, Zhang J, Dashner K, Sar M, Wilson E M, Black P M. Androgen receptor expression in meningiomas.  J Neurosurg . 1995;  82 453-460
    PubMedGoogle Scholar
  • 243 Mailleux P, Przedborski S, Beaumont A. et al . Neurotensin high affinity binding sites and endopeptidase 24.11 are present respectively in the meningothelial and in the fibroblastic components of human meningiomas.  Peptides . 1990;  11 1245-1253
    CrossrefPubMedGoogle Scholar
  • 244 Przedborski S, Levivier M, Cadet J L. Neurotensin receptors in human meningiomas.  Ann Neurol . 1991;  30 650-654
    CrossrefPubMedGoogle Scholar
  • 245 Recht L, Torres C O, Smith T W, Raso V, Griffin T W. Transferrin receptor in normal and neoplastic brain tissue: implications for brain-tumor immunotherapy.  J Neurosurg . 1990;  72 941-945
    PubMedGoogle Scholar
  • 246 Battaini F, Leggio A, Govoni S. et al . Decrease in phorbol ester receptors in human brain tumors.  Eur Neurol . 1990;  30 241-246
    PubMedGoogle Scholar
  • 247 Rudling M J, Angelin B, Peterson C O, Collins V P. Low density lipoprotein receptor activity in human intracranial tumors and its relation to the cholesterol requirement.  Cancer Res . 1990;  50 483-487
    PubMedGoogle Scholar
  • 248 Sawaya R, Yamamoto M, Ramo O J, Shi M L, Rayford A, Rao J S. Plasminogen activator inhibitor-1 in brain tumors: relation to malignancy and necrosis.  Neurosurgery . 1995;  36 375-381
    PubMedGoogle Scholar
  • 249 Shinoura N, Heffelfinger S C, Miller M. et al . RNA expression of complement regulatory proteins in human brain tumors.  Cancer Lett . 1994;  86 143-149
    CrossrefPubMedGoogle Scholar
  • 250 Figarella-Branger D, Pellissier J F, Bouillot P. et al . Expression of neural cell-adhesion molecule isoforms and epithelial cadherin adhesion molecules in 47 human meningiomas: correlation with clinical and morphological data.  Mod Pathol . 1994;  7 752-761
    PubMedGoogle Scholar
  • 251 Yamashima T, Sakuda K, Tohma Y. et al . Prostaglandin D synthase (beta-trace) in human arachnoid and meningioma cells: roles as a cell marker or in cerebrospinal fluid absorption, tumorigenesis, and calcification process.  J Neurosci . 1997;  17 2376-2382
    PubMedGoogle Scholar